Log in
Research report
制药行业2023年三季报总结：至暗已过，看好创新产业链投资机遇-20231103-国泰君安-32页
(行业评级：增持) 三季报总结：院内药品销售有所放缓，创新药刚需价值凸显 Q3由于院内环境收紧，药品学术推广和进院受限，化药和中药板块营收均受不同程度影响，临床疗效优异的创新药依旧保持良好增长态势。随着院内限制因素逐步消除，制药板块增速有望环比逐季改善。生命科学服务、CXO、原料药等细分领域整体尽管仍受2022年新冠高基数影响，但其常规性业务恢复性增长，新兴业务贡献新增量
Read full report →Related industries
No related institutions
Similar reports
- Your Favorite Creator Isn’t Real—Does it Matter?
- FEDS Paper: The Standards Are in the Mail: Comparing Credit Card Supply Indicators
- Six Years of High-Frequency Phone Surveys: Lessons from Sub-Saharan Africa
- The Most Human Technology Ever Made
- The World-Building Doors Are Open, Again.
- Special Economic Zones in South Africa 2026: Policy Review